文献速递颈动脉与弓上血管

颈动脉病变长度独立预测经颈动脉血运重建与经股动脉颈动脉支架术后卒中及死亡

Carotid lesion length independently predicts stroke and death after transcarotid artery revascularization and transfemoral carotid artery stenting.
PubMed 文献 · J Vasc Surg · 2022-07-11

基于血管质量倡议数据库2016至2021年数据,纳入17,931例经颈动脉血运重建(TCAR)和12,036例经股动脉颈动脉支架术(TFCAS)患者,按病变长度<25 mm与≥25 mm分组。长病变与TCAR或TFCAS术后卒中、卒中/短暂性脑缺血发作(TIA)及卒中/死亡风险升高相关;在长病变患者中,TCAR较TFCAS的院内卒中/TIA、卒中、死亡、卒中/死亡及延长住院风险更低。

要点

  • 长颈动脉病变(≥25 mm)与TCAR或TFCAS术后院内卒中、卒中/TIA及卒中/死亡风险升高相关。
  • 长病变患者中,TCAR较TFCAS的卒中/TIA风险降低30%(aOR 0.7,95%CI 0.6-0.9,P=.015)。
  • 长病变患者中,TCAR较TFCAS的院内卒中/死亡风险降低40%(aOR 0.6,95%CI 0.5-0.8,P<.001)。

核心结论

  • 颈动脉病变长度似乎对TCAR和TFCAS的院内结局有负面影响。
  • 病变长度超过25 mm时,TCAR在院内卒中、卒中/TIA、死亡、卒中/死亡及延长住院方面似乎比TFCAS更安全。
  • 这些有利结局似乎证实了血流逆转相较远端栓塞保护装置在神经保护方面的相对优势。

研究设计与样本

  • 回顾性全国队列研究,数据来自血管质量倡议数据库2016至2021年颈动脉支架术患者。
  • 共纳入17,931例TCAR患者(52.6%为长病变)和12,036例TFCAS患者(53.2%为长病变)。
  • 采用限制性立方样条分析描述总体队列中主要结局(院内卒中/死亡)与病变长度的关系,根据曲线斜率变化最显著拐点将病变长度分为<25 mm(短病变)和≥25 mm两组。
  • 将单变量分析中临床相关且统计学显著的变量纳入最终逻辑回归模型,并按中心标识聚类,分析按支架入路分层的病变长度与院内结局的关联。

主要发现

  • 长病变患者在TCAR组中有症状比例更高(27.2% vs 24.3%,P<.001),在TFCAS组中亦有症状比例更高(43.5% vs 38.5%,P<.001)。
  • 长病变患者在TCAR组中更可能接受全身麻醉(84.7% vs 81.9%,P<.001),在TFCAS组中亦更可能接受全身麻醉(21.6% vs 15.8%,P<.001)。
  • 调整潜在混杂因素后,在TCAR或TFCAS患者中,长颈动脉病变与短病变相比,卒中、卒中/TIA及卒中/死亡的比值更高。
  • 长病变患者中,TCAR较TFCAS的卒中/TIA风险降低30%(aOR 0.7,95%CI 0.6-0.9,P=.015),卒中风险降低30%(aOR 0.7,95%CI 0.5-0.9,P=.009),延长住院风险降低30%(aOR 0.7,95%CI 0.6-0.8,P<.001)。
  • 长病变患者中,TCAR较TFCAS的院内卒中/死亡风险降低40%(aOR 0.6,95%CI 0.5-0.8,P<.001),死亡风险降低70%(aOR 0.3,95%CI 0.2-0.4,P<.001)。

关键数值与推荐

  • 病变长度分组阈值:<25 mm为短病变,≥25 mm为长病变。
  • 长病变患者中,TCAR vs TFCAS的卒中/TIA:aOR 0.7(95%CI 0.6-0.9,P=.015)。
  • 长病变患者中,TCAR vs TFCAS的卒中:aOR 0.7(95%CI 0.5-0.9,P=.009)。
  • 长病变患者中,TCAR vs TFCAS的延长住院:aOR 0.7(95%CI 0.6-0.8,P<.001)。
  • 长病变患者中,TCAR vs TFCAS的院内卒中/死亡:aOR 0.6(95%CI 0.5-0.8,P<.001);死亡:aOR 0.3(95%CI 0.2-0.4,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Prior data from the Carotid Revascularization Endarterectomy vs Stenting Trial suggested that the higher perioperative stroke or death event rate among patients treated with transfemoral carotid artery stenting (TFCAS) appears to be strongly related to the lesion length. Nonetheless, data regarding the impact of lesion length on outcomes of transcarotid artery revascularization (TCAR) with flow reversal are lacking. Herein, we aimed to compare the outcomes of TCAR vs TFCAS stratified by the length of the carotid lesion. METHODS: Our cohort was derived from the Vascular Quality Initiative database for carotid artery stenting between 2016 and 2021. Restricted cubic spline analysis was used to describe the relationship between the primary outcome (in-hospital stroke/death) and the exposure variable (lesion length) in the overall cohort. This relationship was not linear, and knots were identified where significant changes in the slope of the curve occurred. We therefore divided patients based on knot with the most significant inflection into two groups: lesion length <25 mm (short) and lesion length ≥25 mm. Clinically relevant and statistically significant variables on univariable analysis were added to the final logistic regression model clustered by center identifier to study the association between lesion length and in-hospital outcomes stratified by the stent approach. RESULTS: The study cohort included 17,931 TCAR (52.6% with long lesions) and 12,036 TFCAS (53.2% with long lesions) patients. Patients with long lesions had higher rates of being symptomatic among both TCAR (27.2% vs 24.3%, P < .001) and TFCAS (43.5% vs 38.5%, P < .001) and were more likely to undergo general anesthesia in TCAR (84.7% vs 81.9%, P < .001) and TFCAS (21.6% vs 15.8%, P < .001). After adjusting for potential confounders, long carotid lesions were associated with higher odds of stroke, stroke/transient ischemic attack (TIA), and stroke/death compared with short lesions among patients who underwent TCAR or TFCAS. However, when comparing TCAR vs TFCAS outcomes in patients with long lesions, TCAR was found to be associated with a 30% reduction in stroke/TIA (adjusted odds ratio [aOR]: 0.7, 95% confidence interval [CI]: 0.6-0.9, P = .015), stroke (aOR: 0.7, 95% CI: 0.5-0.9, P = .009), and extended length of stay (ELOS) (aOR: 0.7, 95% CI: 0.6-0.8, P < .001). There was also a 40% reduction in the odds of in-hospital stroke/death (aOR: 0.6, 95% CI: 0.5-0.8, P < .001) and a 70% reduction in mortality (aOR: 0.3, 95% CI: 0.2-0.4, P < .001) in TCAR compared with TFCAS. CONCLUSIONS: In this large contemporary retrospective national study, carotid lesion length appears to negatively impact in-hospital outcomes for TCAR and TFCAS. In the presence of lesions longer than 25 mm, TCAR appears to be safer than TFCAS with regard to the risk of in-hospital stroke, stroke/TIA, death, stroke/death, and ELOS. These favorable outcomes seem to confirm the relative advantage of flow reversal compared with distal embolic protection devices in terms of neuroprotection.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Elsayed N, Khan MA, Moacdieh MP, et al. Carotid lesion length independently predicts stroke and death after transcarotid artery revascularization and transfemoral carotid artery stenting. J Vasc Surg. 2022. PMID: 35835322. doi:10.1016/j.jvs.2022.06.099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。